JP2024506882A5 - - Google Patents
Info
- Publication number
- JP2024506882A5 JP2024506882A5 JP2023547506A JP2023547506A JP2024506882A5 JP 2024506882 A5 JP2024506882 A5 JP 2024506882A5 JP 2023547506 A JP2023547506 A JP 2023547506A JP 2023547506 A JP2023547506 A JP 2023547506A JP 2024506882 A5 JP2024506882 A5 JP 2024506882A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide chain
- chemical modification
- nucleotides
- activated rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110175652 | 2021-02-07 | ||
| CN202110175652.9 | 2021-02-07 | ||
| CN2021075958 | 2021-02-08 | ||
| CNPCT/CN2021/075958 | 2021-02-08 | ||
| PCT/CN2022/074635 WO2022166814A1 (zh) | 2021-02-07 | 2022-01-28 | 一种化学修饰的小激活rna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506882A JP2024506882A (ja) | 2024-02-15 |
| JP2024506882A5 true JP2024506882A5 (enExample) | 2025-02-04 |
Family
ID=82741987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547506A Pending JP2024506882A (ja) | 2021-02-07 | 2022-01-28 | 化学修飾された低分子活性化ｒｎａ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240301409A1 (enExample) |
| EP (1) | EP4289952A4 (enExample) |
| JP (1) | JP2024506882A (enExample) |
| KR (1) | KR20230142774A (enExample) |
| CN (1) | CN116829716A (enExample) |
| WO (1) | WO2022166814A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025021186A1 (en) * | 2023-07-27 | 2025-01-30 | Ractigen Therapeutics | Glycerol nucleic acid modified oligonucleotide agents and use thereof |
| WO2025224036A1 (en) * | 2024-04-22 | 2025-10-30 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1871426B1 (en) * | 2005-04-15 | 2017-06-07 | The Regents of The University of California | Small activating rna molecules and their use |
| US9045751B2 (en) * | 2010-04-28 | 2015-06-02 | The Regents Of The University Of California | Modified small activating RNA molecules and methods of use |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| SI3071696T1 (sl) * | 2013-11-22 | 2019-11-29 | Mina Therapeutics Ltd | C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe |
| KR102599712B1 (ko) * | 2015-04-22 | 2023-11-09 | 미나 테라퓨틱스 리미티드 | C/EBP 알파 saRNA 조성물 및 사용 방법 |
| CN109563511A (zh) | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US20200208152A1 (en) * | 2017-09-08 | 2020-07-02 | Mina Therapeutics Limited | Stabilized sarna compositions and methods of use |
| WO2019048632A1 (en) * | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE |
| US20210332366A1 (en) * | 2018-04-10 | 2021-10-28 | Ractigen Therapeutics | Novel Small Activating RNA |
| WO2019196883A1 (zh) * | 2018-04-10 | 2019-10-17 | 中美瑞康核酸技术(南通)研究院有限公司 | 一种激活p21基因表达的方法 |
-
2022
- 2022-01-28 US US18/275,900 patent/US20240301409A1/en active Pending
- 2022-01-28 EP EP22749093.5A patent/EP4289952A4/en active Pending
- 2022-01-28 JP JP2023547506A patent/JP2024506882A/ja active Pending
- 2022-01-28 WO PCT/CN2022/074635 patent/WO2022166814A1/zh not_active Ceased
- 2022-01-28 KR KR1020237030334A patent/KR20230142774A/ko active Pending
- 2022-01-28 CN CN202280013796.7A patent/CN116829716A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6959293B2 (ja) | Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 | |
| Gryaznov | Oligonucleotide N3′→ P5′ phosphoramidates as potential therapeutic agents | |
| JP2024056820A (ja) | Ｓｃｎ９ａ発現を調節するためのオリゴヌクレオチド | |
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| Gryaznov | Oligonucleotide N3′→ P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents | |
| EP0736093B1 (en) | ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL | |
| JP7798836B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2023537798A5 (enExample) | ||
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| JPH09510714A (ja) | オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
| JP2003505080A (ja) | ヒトｅｇ５の発現を阻害するためのオリゴヌクレオチド | |
| JP2024506882A5 (enExample) | ||
| EP3532617B1 (en) | Antisense oligonucleotides | |
| WO2025157271A1 (zh) | 一种抑制f11基因表达的核酸分子 | |
| JP2023506546A (ja) | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 | |
| JP5121106B2 (ja) | ホルモン制御腫瘍のアンチセンス治療法 | |
| JP2023538630A (ja) | Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用 | |
| NZ524274A (en) | Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy | |
| WO2010032704A1 (ja) | マイクロｒｎａ―１４３誘導体を含有する医薬 | |
| JP2002501505A (ja) | ヒトＨａ−ｒａｓ遺伝子断片に相補的な修飾アンチセンスヌクレオチド | |
| JP2013534410A5 (enExample) | ||
| CN119790155A (zh) | 苏糖核酸反义寡核苷酸及其方法 | |
| Morassutti et al. | Reduction of mdrl Gene Amplification in Human Multidrug-Resistant LoVo DX Cell Line Is Promoted by Triple Helix-Forming Oligonucleotides | |
| JP7813254B2 (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| CN121204147A (zh) | 靶向rna修饰调控的方法 |